# Immuneering Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immuneering

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.immuneering.com
- Total disclosed funding: $57M
- Latest round: Series B (Dec 21, 2020)
- Investors on record: 8

## About

Based in Massachusetts, US, and founded in 2008, Immuneering Corporation operates as a bioinformatics company that develops and researches treatments for cancer cachexia and metastasis. The company has 32 employees as of July 2021 and was co-founded by Ben Zeskind (CEO) and Bob Carpenter. In July 2021, Immuneering raised USD 112.50 million in an IPO, selling 7.5 million shares at USD 15 per share on the Nasdaq.

Immuneering Corporation develops proprietary Disease Cancelling Technology (DCT) where they use a method for reversing a disease signal across many relevant genes. The company also provides Dual MEK, Covalent MEK, and KRAS4B that focus on the discovery stage of drug development.

Immuneering Corporation plans to develop its Disease Cancelling Technology (DCT) platform, enhance its computational biology services business, and submit an IND for IMM-1-104 in the first quarter of 2022.

## Funding rounds

- Series B, Dec 21, 2020, $37M — T Rowe Price, Surveyor Capital, BlackRock, Rock Springs Capital, Cormorant Asset Management, Perceptive Advisors, LYFE Capital
- Series A, Jan 6, 2020, $20M — Boxcar

## Investors

- Boxcar (https://capitalatlas.ai/funds/boxcar) — Series A
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Surveyor Capital — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Rock Springs Capital — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- LYFE Capital — Series B